Literature DB >> 19179271

Different apparent prognostic value of hsCRP in type 2 diabetic and nondiabetic patients with acute coronary syndromes.

Luigi M Biasucci1, Giovanna Liuzzo, Roberta Della Bona, Milena Leo, Gina Biasillo, Dominick J Angiolillo, Antonio Abbate, Vittoria Rizzello, Giampaolo Niccoli, Simona Giubilato, Filippo Crea.   

Abstract

BACKGROUND: C-reactive protein (CRP) is an established prognostic marker in acute coronary syndromes (ACS); however, no study has specifically addressed its prognostic role in type 2 diabetes with ACS. We evaluated the prognostic role of CRP separately in diabetic and nondiabetic patients with ACS.
METHODS: We enrolled 251 patients with unstable angina and measured serum concentrations of high sensitivity (hs)CRP. Ninety-seven patients underwent coronary angiography with evaluation of atherosclerotic disease severity and extent by Bogaty score. Assessed endpoint was the combined occurrence of myocardial infarction (MI) and death at 1 year.
RESULTS: No significant differences were found in hs-CRP between patients with and without diabetes. By Cox regression, hsCRP was not associated with 1-year follow-up events in diabetic patients but was strongly associated with events in nondiabetic patients (P = 0.0012). Coronary angiography exhibited a higher extent index in patients with diabetes than in those without (P = 0.04). hsCRP concentrations were not associated with angiographic atherosclerotic burden. By Cox analysis, hsCRP and extent score were associated with events in patients who underwent coronary angiography (P < 0.001 and P = 0.034, respectively). In nondiabetic patients, hsCRP was the only predictor of events at 1-year follow-up (P < 0.001), whereas in diabetic patients, hsCRP was not associated with events and a weak association was observed for extent score (P = 0.06).
CONCLUSIONS: Our study suggests that different pathophysiological mechanisms may be responsible for MI and death in unstable angina patients with or without diabetes and that severity of coronary artery disease plays a major role in diabetes (and inflammation in the absence of diabetes).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19179271     DOI: 10.1373/clinchem.2008.119156

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  9 in total

Review 1.  Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?

Authors:  Iciar Martín-Timón; Cristina Sevillano-Collantes; Amparo Segura-Galindo; Francisco Javier Del Cañizo-Gómez
Journal:  World J Diabetes       Date:  2014-08-15

2.  Admission C-reactive protein and short- as well as long-term mortality in diabetic versus non-diabetic patients with incident myocardial infarction.

Authors:  C Meisinger; M Heier; W von Scheidt; B Kuch
Journal:  Clin Res Cardiol       Date:  2010-07-02       Impact factor: 5.460

3.  High-sensitivity C-reactive protein and hypertension: combined effects on coronary severity and cardiovascular outcomes.

Authors:  Hui-Hui Liu; Ye-Xuan Cao; Di Sun; Jing-Lu Jin; Hui-Wen Zhang; Yuan-Lin Guo; Cheng-Gang Zhu; Na-Qiong Wu; Ying Gao; Qiu-Ting Dong; Jian-Jun Li
Journal:  Hypertens Res       Date:  2019-06-25       Impact factor: 3.872

4.  Association of C-reactive protein with cardiovascular disease mortality according to diabetes status: pooled analyses of 25,979 participants from four U.K. prospective cohort studies.

Authors:  Andre Pascal Kengne; G David Batty; Mark Hamer; Emmanuel Stamatakis; Sébastien Czernichow
Journal:  Diabetes Care       Date:  2011-12-30       Impact factor: 19.112

5.  Toll-like receptor 4 rs11536889 is associated with angiographic extent and severity of coronary artery disease in a Chinese population.

Authors:  Dandan Sun; Yupeng Wu; Honghu Wang; Hong Yan; Wen Liu; Jun Yang
Journal:  Oncotarget       Date:  2017-01-10

6.  Adaptive immunity, inflammation, and cardiovascular complications in type 1 and type 2 diabetes mellitus.

Authors:  Daniela Pedicino; Giovanna Liuzzo; Francesco Trotta; Ada Francesca Giglio; Simona Giubilato; Francesca Martini; Francesco Zaccardi; Giuseppe Scavone; Marco Previtero; Gianluca Massaro; Pio Cialdella; Maria Teresa Cardillo; Dario Pitocco; Giovanni Ghirlanda; Filippo Crea
Journal:  J Diabetes Res       Date:  2013-05-23       Impact factor: 4.011

Review 7.  Cardiovascular risk assessment in patients with diabetes.

Authors:  Marcello Casaccia Bertoluci; Viviane Zorzanelli Rocha
Journal:  Diabetol Metab Syndr       Date:  2017-04-20       Impact factor: 3.320

8.  High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial.

Authors:  You-Cheol Hwang; David A Morrow; Christopher P Cannon; Yuyin Liu; Richard Bergenstal; Simon Heller; Cyrus Mehta; William Cushman; George L Bakris; Faiez Zannad; William B White
Journal:  Diabetes Obes Metab       Date:  2017-11-21       Impact factor: 6.577

9.  Inflammatory markers and risk of cardiovascular mortality in relation to diabetes status in the HUNT study.

Authors:  Lena Løfblad; Gunhild Garmo Hov; Arne Åsberg; Vibeke Videm
Journal:  Sci Rep       Date:  2021-08-02       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.